ID
23898
Description
Study part: Non- Serious Adverse Events. A phase 2 study to assess safety, reactogenicity and immunogenicity of a booster dose of an investigational vaccination regimen and GSK Biologicals Hib-MenC vaccine (co-administered with Infanrix penta) compared to a booster dose of Menjugate (co-administered with Infanrix hexa).Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Study ID: 100381, Clinical Study ID: 100381
Keywords
Versions (1)
- 7/17/17 7/17/17 -
Copyright Holder
GlaxoSmithKline
Uploaded on
July 17, 2017
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Non- Serious Adverse Events Hib-MenCY-TT-004 BST 003 Neisseria Meningitidis-Haemophilus influenzae type b Vaccine 100381
Non- Serious Adverse Events
- StudyEvent: ODM
Similar models
Non- Serious Adverse Events
- StudyEvent: ODM
C1518404 (UMLS CUI [1,2])
C0042210 (UMLS CUI [1,2])
C0013227 (UMLS CUI [1,2])
C0008972 (UMLS CUI [1,3])